The aim of this core is to provide state of the art translational research support services for the novel cellular and immune-based therapies described in the projects in this proposal. Specifically, Core C personnel will perform the large scale production of the NK cell, Treg and Tprog products for the clinical trials in a GMP facility. The Core will also be responsible for the comprehensive immune monitoring of patient and product samples to assess the success of the novel experimental therapies described in Project 1 (T regulatory cells, PI: JE Wagner) and Project 3 (NK cells, PI: JS Miller). Core personnel work closely with the research staff from Core A (Administration) and with the biostatistics and data management staff (Core B: Biostatistics) to facilitate collection and tracking of clinical research samples and provide investigators with complete and accurate immune monitoring data which can be integrated with clinical outcome data.
The Specific Aims of Core C are: 1. To perform large-scale production of NK, Treg and Tprog cells products in a GMP facility 2. To monitor the quality of clinical GMP products 3. To perform comprehensive immune monitoring of patient samples 4. To assist with integration of research and clinical outcome data

Public Health Relevance

Core C supports sample collection, GMP cell product processing and immune monitoring for this program. Immune monitoring is critical for the interpretation of the clinical trials and to help trouble-shoot problems. The Core's shared resources are critical to the scientific integrity between projects and this Program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Bunting, Mark D; Varelias, Antiopi; Souza-Fonseca-Guimaraes, Fernando et al. (2017) GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. Blood 129:630-642
Smith, Michelle J; Reichenbach, Dawn K; Parker, Sarah L et al. (2017) T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. JCI Insight 2:
Kean, Leslie S; Turka, Laurence A; Blazar, Bruce R (2017) Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev 276:192-212
Barker, Juliet N; Kurtzberg, Joanne; Ballen, Karen et al. (2017) Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 23:882-896
He, Fiona; Cao, Qing; Lazaryan, Aleksandr et al. (2017) Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Transplant 23:1485-1490
Webber, Beau R; O'Connor, Kyle T; McElmurry, Ron T et al. (2017) Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Lab Invest 97:1218-1224
Fair, C; Shanley, R; Rogosheske, J et al. (2017) BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. Bone Marrow Transplant 52:491-493
Skvarova Kramarzova, Karolina; Osborn, Mark J; Webber, Beau R et al. (2017) CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. Int J Mol Sci 18:
Pourhassan, H; DeFor, T; Trottier, B et al. (2017) MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes. Bone Marrow Transplant 52:532-538
Kamphorst, Alice O; Wieland, Andreas; Nasti, Tahseen et al. (2017) Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355:1423-1427

Showing the most recent 10 out of 353 publications